26/06/2023 – AB Science today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating (mCRPC) with its lead compound masitinib, based on findings from study AB12003
01/06/2023 – AB Science today announced that the patent office of Canada has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib
30/05/2023 – AB Science will hold its Annual General Meeting on Friday 30 June 2023 at 3.30pm
17/05/2023 – AB Science today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023)
09/05/2023 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
28/04/2023 – AB Science reports its revenues for the year 2022 and provides an update on its activities
27/04/2023 – AB Science today summarizes the presentation that was made on masitinib in amyotrophic lateral sclerosis at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston, USA
27/04/2023 – Presentation on masitinib in amyotrophic lateral sclerosis delivered at the American Academy of Neurology 2023 Annual Meeting
24/04/2023 – AB Science announces today the success of its capital increase via a private placement for a final amount of 15.0 million euros
21/04/2023 – AB Science announces today the implementation of a new strategy and the launch, in support of this new strategy, of a capital increase